Evidence map›Paper›PMID 39336408›Full record

ArticleMaterials (Basel, Switzerland)2024

On the Creation of a Material Bond between L-PBF-Manufactured AZ91 and Ti-6Al-4V Components in the Context of Medical Applications.

Lennart Grüger, Felix Jensch, Fabian Dittrich, Sebastian Härtel

Abstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lennart GrügerDepartment Hybride Manufacturing, BTU Cottbus Senftenberg, Konrad-Wachsmann-Allee 17, 03046 Cottbus, Germany.ORCID 0000-0001-8209-7229
Felix JenschDepartment Hybride Manufacturing, BTU Cottbus Senftenberg, Konrad-Wachsmann-Allee 17, 03046 Cottbus, Germany.
Fabian DittrichDepartment Hybride Manufacturing, BTU Cottbus Senftenberg, Konrad-Wachsmann-Allee 17, 03046 Cottbus, Germany.
Sebastian HärtelDepartment Hybride Manufacturing, BTU Cottbus Senftenberg, Konrad-Wachsmann-Allee 17, 03046 Cottbus, Germany.ORCID 0000-0001-8927-0573

Funding

Deutsche Forschungsgemeinschaft 534007237
6 · The paper itself

Abstract

Within the scope of these investigations, the feasibility of a material bond between Ti-6Al-4V and the magnesium alloy AZ91 is analyzed. Ti-6Al-4V is frequently used for implants due to its biocompatibility, corrosion resistance, and specific strength. However, depending on the surface quality, the attachment behavior of the bone to the implant varies. Magnesium implants promote the regeneration of bone tissue and biodegrade as the bone tissue heals. Combining the properties of both materials in one implant enables a reduced implant volume and increased stability. For this reason, this study aims to demonstrate the feasibility of creating a material bond between the materials Ti-6Al-4V and AZ91. For this purpose, Ti-6Al-4V truncated cones and AZ91 sleeves were produced using the additive manufacturing process of laser powder bed fusion (L-PBF). The as-built sleeves were then pressed onto machined truncated cones. Since zinc serves as a lubricant and has good diffusion properties with the materials used as a result of heat treatment, a comparison was made between zinc-coated and the as-built Ti-6Al-4V samples. This showed that a bond was created after hot isostatic pressing and that the push-out force could be increased by more than 4.5 times. Consequently, a proof of feasibility was demonstrated, and a high potential for applications in medical technology was shown.

Indexed as

additive manufacturingAZ91implant technologyL-PBFTi-6Al-4V

Identifiers

PMID39336408
PMCPMC11434085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.